Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,02
KB-1,60
PKN123,5123,71,64
Msft0,03
IBM-1,55
DCX68,7568,760,59
PFE-0,05
24.10.2017 1:38:04
Indexy online
AD Index online
select
AD Index online
 

  • 16.6.2017 11:44:10
NetScientific (London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
0,4825 0,00 0,00 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.10.2017
Popis společnosti
Obecné informace
Název společnostiNetscientific PLC
TickerNSCI
Kmenové akcie:Ordinary Shares
RICNSCI.L
ISINGB00B9F4MT28
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2014 23
Akcie v oběhu k 30.6.2017 69 038 057
MěnaGBP
Kontaktní informace
Ulice30 St. Mary Axe
MěstoLONDON
PSČEC3A 8BF
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon442 035 141 800

Business Summary: NetScientific plc is a transatlantic healthcare technology company. The Company develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the United States and Europe with a primary focus on diagnostics, digital health and therapeutics. The Company is engaged in the development of intellectual property. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients; Glucosense, a provider of a non-invasive glucose monitoring wearable device; Vortex Biosciences, which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing; Glycotest, which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis, and ProAxsis, which is engaged in respiratory disease diagnosis and treatment monitoring.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Netscientific PLC revenues decreased 54% to L164K. Net loss before extraordinary items decreased 12% to L4.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development costs decrease of 18% to L3M (expense), Other operang income increase from L4K to L222K (income).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Medical Diagnostic & Testing Equipment
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSInVitro Diagnostic Substance Manufacturing
NAICSOther Measuring and Controlling Device Manufacturing
SICElectromedical Equipment
SICCommercial Physical Research
SICDiagnostic Substances
SICMeasuring/controlling Devices Nec



  • Poslední aktualizace: 24.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman, Executive DirectorRichard Skyes-
Chief Financial Officer, DirectorIan Postlethwaite-15.6.201613.6.2016
Chief Executive Officer of Glycotest Inc.Lawrence Cohen-4.1.20164.1.2016
Chief Executive Officer of Vortex BioSciencesGene Walther584.1.20164.1.2016